Kisho is an information platform, not a medical provider. Nothing on this site constitutes medical advice, diagnosis, or treatment recommendations. All content is aggregated from publicly available sources (including ClinicalTrials.gov, PubMed, FDA.gov, and Orphanet) and is provided for informational purposes only. Clinical trial eligibility, treatment decisions, and any health-related actions should always be discussed with a qualified healthcare professional. Kisho does not endorse any specific therapy, organization, or clinical trial. Terms of use · Privacy policy
A differentiated adenocarcinoma arising from the follicular cells of the thyroid gland. Radiation exposure is a risk factor and it is the most common malignant thyroid lesion, comprising 75% to 80% of all thyroid cancers in iodine sufficient countries. Diagnostic procedures include thyroid ultrasound and fine needle biopsy. Microscopically, the diagnosis is based on the distinct characteristics of the malignant cells, which include enlargement, oval shape, elongation, and overlapping of the nuclei. The nuclei also display clearing or have a ground glass appearance.
58 clinical trials registered, 24 recruiting. Interventions under study include other interventions, procedural interventions, drug therapy, and medical devices. Pipeline includes 1 PHASE4, 3 PHASE3, 13 PHASE2. Research is sponsored by a mix of industry and academic institutions.
NCT ID | Title | Phase | Sponsor | Status |
|---|---|---|---|---|
[NCT05766098](https://clinicaltrials.gov/study/NCT05766098) |
Data assembled from 3 of 12 sources · Last updated Nov 3, 2026, 6:00 AM UTC
Definition of Mutational Profile of Papillary Thyroid Tumors by Mass-ARRAY |
— |
Istituto Auxologico Italiano |
RECRUITING |
[NCT06082180](https://clinicaltrials.gov/study/NCT06082180) | A Prospective, Open-label, Multicenter, Randomized Controlled Phase III Study of Prophylactic Central Neck Dissection in Low-risk Papillary Thyroid Cancer | PHASE3 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | RECRUITING |
[NCT06133374](https://clinicaltrials.gov/study/NCT06133374) | Concordance of Molecular Classification Based on Fine Needle Biopsy (FNB) and Surgical Samples | — | University of Calgary | RECRUITING |
[NCT06087068](https://clinicaltrials.gov/study/NCT06087068) | Thyroxine Replacement Therapy After Lobectomy for Low-risk Papillary Thyroid Carcinoma | PHASE2 | Cancer Institute and Hospital, Chinese Academy of Medical Sciences | RECRUITING |
[NCT06791005](https://clinicaltrials.gov/study/NCT06791005) | A Clinical Study on the Benefits of Carbon Nanoparticles Injection Time in Patients With Thyroid Cancer. | PHASE3 | Second Affiliated Hospital of Xi'an Jiaotong University | RECRUITING |
5 publications have been identified in PubMed for thyroid gland papillary carcinoma. Research spans Case Report / Case Series (80%) and Epidemiology / Natural History (20%).
Jacob A (2025). [PMID: 40636652](https://pubmed.ncbi.nlm.nih.gov/40636652/). *Cureus*. [Case Report / Case Series]
Yunatanov A (2025). [PMID: 41450425](https://pubmed.ncbi.nlm.nih.gov/41450425/). *Cureus*. [Case Report / Case Series]
Balaji AN (2025). [PMID: 40125144](https://pubmed.ncbi.nlm.nih.gov/40125144/). *Cureus*. [Case Report / Case Series]
Al-Haideri MH (2024). [PMID: 39087148](https://pubmed.ncbi.nlm.nih.gov/39087148/). *Cureus*. [Epidemiology / Natural History]
Sierra Castillo S (2024). [PMID: 39553134](https://pubmed.ncbi.nlm.nih.gov/39553134/). *Cureus*. [Case Report / Case Series]
AI-curated news mentioning thyroid gland papillary carcinoma
Updated Oct 5, 2026
A new study explores the effectiveness of staged surgical resection for adrenal metastasis originating from papillary thyroid cancer. This research contributes to understanding treatment options for patients with advanced thyroid cancer.
A new study highlights the diffuse sclerosing variant of papillary thyroid carcinoma as a rare and invasive cancer in childhood. This research underscores the challenges in diagnosing and treating this specific cancer variant.
Recent research highlights the impact of TERT promoter variants and older age on the prognosis of papillary thyroid carcinoma. This study provides insights that could influence future treatment strategies and patient management.